Search results for "Newly diagnosed"

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results f…

2021

Abstract Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM. Patients and Methods: Patients were equally randomized into four treatment arms, stratified by International Staging System (ISS). Treatment consisted of four 21-da…

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysi…

2021

Abstract Background: During the past decade, prognostic tools and outcomes of patients with newly-diagnosed multiple myeloma (NDMM) markedly improved. Data from clinical trials evaluating early morbidity and mortality including patients with transplant-eligible NDMM treated with novel agents are scarce. Thus, we aimed to analyze early morbidity and mortality in this patient cohort, devise and validate a predictive score to identify patients at risk. Patients and methods: Between July 2005 and January 2018, 1333 patients with transplant-eligible NDMM from three subsequent phase III trials, HD4, MM5 and HD6 from the German-speaking Myeloma Multicenter Group (GMMG), received a novel agent-base…

Sparassidae from Japan. II. First Pseudopoda species and new Sinopoda species (Araneae: Sparassidae: Heteropodinae)

2002

The genus Pseudopoda is recorded for the first time from Japan. Pseudopoda kasariana sp. nov. (_??_, _??_) and Pseudopoda spirembolus sp. nov. (_??_, _??_) are described from Amami-oshima Island and Okinawajima Island respectively. Four new Sinopoda species are described: Sinopoda albofasciata (_??_), Sinopoda derivata (_??_, _??_), Sinopoda ogatai (_??_, _??_) and Sinopoda stellatops (_??_, _??_). Sinopoda koreana (Paik 1968) is recorded for the first time from Japan. New records of Sinopoda okinawana Jager & Ono 2000 and S. tanikawai Jager & Ono 2000 are presented. Within the genus Sinopoda Jager 1999 the okinawana species-group is newly diagnosed, which is represented by S. albofasciata …

Response to: Is newly diagnosed diabetes a stronger risk factor than pre‐existing diabetes for COVID ‐19 severity?

2020

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

Mucormycosis of maxillary sinus in a newly diagnosed case of diabetes mellitus

2019

Rhinocerebral mucormycosis is the third most common fungal infection after aspergillosis and candidiasis. The importance of mucormycosis has grown in recent years, as the number of patients has increased dramatically. Herein, we present a case of a newly diagnosed patient of diabetes mellitus having ulcerated palate and destruction of maxillary sinus evident on computed tomography scan. A biopsy report was suggestive of mucormycosis. Aggressive medical and surgical treatment was done along with the treatment of diabetes mellitus.

Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

2016

Purpose To compare whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI), FDG-PET/CT, and bone marrow biopsy (BMB), for the evaluation of bone marrow involvement (BMI) in patients with newly diagnosed lymphoma. Materials and Methods This retrospective study was approved by our Institutional Review Board. Two independent radiologists and one nuclear medicine specialist reviewed all WB-MRI and FDG-PET/CT scans prospectively performed on 104 patients with newly diagnosed lymphoma (53 males; 47 Hodgkin; mean age: 44 years; range, 15–86 years) between 2013 and 2015. The delay between imaging scans and BMBs was up to 10 days. The diagnostic accuracy of WB-MRI (1.5 Tesla MR scanner, with T…